Xspray Pharma Valuation

Is XSPRAS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XSPRAS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XSPRAS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XSPRAS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XSPRAS?

Key metric: As XSPRAS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for XSPRAS. This is calculated by dividing XSPRAS's market cap by their current book value.
What is XSPRAS's PB Ratio?
PB Ratio	2.6x
Book	SEK 668.14m
Market Cap	SEK 1.75b

XSPRAS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-7.9x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does XSPRAS's PB Ratio compare to its peers?

The above table shows the PB ratio for XSPRAS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	43.7x
FARN Faron Pharmaceuticals Oy	152.8x	17.3%	UK£175.2m
AVCT Avacta Group	3.6x	-2.1%	UK£173.8m
BVXP Bioventix	16.4x	n/a	UK£197.0m
ETX e-therapeutics	1.9x	n/a	UK£52.6m
XSPRAS Xspray Pharma	2.6x	122.4%	SEK 1.7b

Price-To-Book vs Peers: XSPRAS is good value based on its Price-To-Book Ratio (2.6x) compared to the peer average (9.5x).

Price to Book Ratio vs Industry

How does XSPRAS's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 Companies	Price / Book	Estimated Growth	Market Cap
DEST Destiny Pharma	0.3x	-15.5%	US$5.85m
BDRX Biodexa Pharmaceuticals	0.5x	n/a	US$4.42m
LLAI LungLife AI	0.5x	101.0%	US$3.60m
VAL ValiRx	0.6x	n/a	US$2.81m

No more companies available in this PB range

4 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: XSPRAS is expensive based on its Price-To-Book Ratio (2.6x) compared to the UK Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is XSPRAS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XSPRAS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.6x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate XSPRAS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.2b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$753.98

0.6%

-8.0%

Formycon

€882.8m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€50.00

7.5%

-24.1%

hVIVO

UK£146.3m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

-6.1%

3.4%